Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticholinergic bronchodilators.

T J Witek1

  • 1Department of Clinical Research, Respiratory and Immunology, BoehringerIngelheim Pharmaceuticals, Inc., Ridgefield, Connecticut twitek@rdg.boehringer-ingelheim.com

Respiratory Care Clinics of North America
|November 24, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A "Tail" of three cities. Public health and acute atrophy of vigilance.

Public health·2023
Same author

Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease.

Thorax·2003
Same author

Minimal important difference of the transition dyspnoea index in a multinational clinical trial.

The European respiratory journal·2003
Same author

Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity.

Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine·2001
Same author

Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD.

Chest·2001
Same author

Inhaled anticholinergic therapy: applied pharmacology and interesting developments.

Current opinion in investigational drugs (London, England : 2000)·2001

Antimuscarinic agents like ipratropium bromide are effective bronchodilators for chronic obstructive pulmonary disease (COPD). New long-acting antimuscarinic drugs, such as tiotropium, offer promising once-daily treatment options for COPD patients.

Area of Science:

  • Pulmonology
  • Pharmacology

Background:

  • Antimuscarinic agents have a historical role in treating airway diseases.
  • Current formulations include ipratropium bromide, a recognized bronchodilator and antisecretory agent for COPD and rhinorrhea.

Purpose of the Study:

  • To review the established efficacy of antimuscarinic treatments in COPD.
  • To discuss the role of ipratropium bromide and emerging long-acting agents like tiotropium.

Main Methods:

  • Review of existing literature on antimuscarinic therapies for airway diseases.
  • Analysis of spirometry data supporting bronchodilation effects.
  • Examination of evidence regarding anticholinergic impact on COPD physiology.

Main Results:

Related Experiment Videos

  • Ipratropium bromide is a safe and effective bronchodilator for COPD, proven by spirometry.
  • Anticholinergics may influence dynamic hyperinflation in COPD.
  • Long-acting antimuscarinic agents, like tiotropium, are under development for once-daily use.

    • Conclusions:

    • Antimuscarinic therapy, particularly ipratropium bromide, remains a cornerstone in COPD management.
    • Further research is needed to fully understand the long-term physiological effects and health outcomes.
    • The development of once-daily tiotropium represents a significant advancement in antimuscarinic treatment for COPD.